Navigation Links
RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
Date:1/14/2014

WESTBOROUGH, Mass., Jan. 14, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it received the Notice of Allowance from the United States Patent and Trademark Office on its unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF, including RXI-109, for the treatment of fibrotic disorders. The patent, once issued, will be scheduled to expire in 2029.

"This notice of allowance from the USPTO is of high importance for RXi's Intellectual Property position in the RNAi field, and more specifically in the space of skin and organ fibrosis," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, "Our sd-rxRNA compound, RXI-109 targeting CTGF, has already demonstrated excellent safety results in our Phase 1 trials and has confirmed the mechanism of action of this self-delivering RNAi in humans in a dose dependent manner. This patent enhances our ability to broadly protect our proprietary technology, including our anti-fibrotic compounds, reinforcing the potential for future commercial and business development opportunities."

About RXI-109

RXi Pharmaceuticals' first clinical program involves RXI‑109, a self-delivering RNAi compound (sd‑rxRNA®) developed for the reduction of dermal scarring. RXI‑109 is designed to reduce the expression of CTGF, a critical regulator of biological pathways involved in fibrosis, including scar formation in the skin. The first clinical trials with RXI‑109 showed excellent safety and tolerability with ascending single and multiple doses, as well as dose dependent effects on the Connective Tissue Growth Factor protein an
'/>"/>

SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 OriginOil Inc. ... high-speed, chemical-free process to clean up large quantities of ... CEO Riggs Eckelberry reported on the launch of the ... a site provided by partner STW Resources . ... 1000 barrels per day (bpd) and achieved a 99.8% ...
(Date:9/30/2014)... BioHealth Innovation, Inc. (BHI), a ... and increasing access to early-stage funding in ... Tania Fernandez , Ph.D., has joined the BHI ... a member of the management team for a new ... million in seed and early-stage equity investments to therapeutics, ...
(Date:9/30/2014)... September 30, 2014 iLab Solutions announced ... Benchmarking study which focuses on core facility operations, ... core managers face today. , In its 4th year ... of note is the year-over-year decrease in the percentage ... appear to be feeling the constraints of this trend. ...
(Date:9/30/2014)... The custom stainless steel fabrication company HOLLOWAY AMERICA ... Boston Area Chapter of ISPE (International Society for Pharmaceutical ... Wed., Oct. 1 at Gillette Stadium Clubhouse in Foxborough, ... ISPE Boston’s long history, with more than 375 exhibitors ... , HOLLOWAY AMERICA President David Simpson is looking forward ...
Breaking Biology Technology:OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today ... of its manufacturing process for,REOLYSIN(R) to commercial ... production and downstream processing,development was undertaken by ... located in Montreal, Canada., "Our existing ...
... Industry Expertise to Pathwork Following FDA ... Clearance and $20M Fundraising Round, SUNNYVALE, ... on oncology, announced today the,appointment of two key positions within ... Mark McDonough as Vice,President of US Sales. These professionals bring ...
... CJPS Enterprises, LLC, (http://www.CJPS-Enterprises.com ), the operator ... ) is announcing a new service available,to ... business, or looking to,invest in Michigan companies ... existing resources available on the Michigan Life ...
Cached Biology Technology:Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale 2Pathwork Diagnostics Announces Key Additions to Management Team 2The Michigan Life Sciences Pipeline Announces 'The Funding Place(TM)' and Other Resources to Connect Investors and Startups 2
(Date:9/30/2014)... 30, 2014) People who suffer from asthma may ... control their asthma besides properly taking medications and avoiding ... in the Annals of Allergy, Asthma and Immunology ... Allergy, Asthma and Immunology (ACAAI), asthma sufferers can learn ... The woman described in the Annals article improved her ...
(Date:9/29/2014)... ramosum , coupled with a high-fat diet, may cause animals ... mBio , the online open-access journal of the American ... German Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal observed that ... gained weight when fed a high-fat diet. Mice that did ... when consuming a high-fat diet, and mice that had ...
(Date:9/29/2014)... 29, 2014 -- Plants have a symbiotic relationship ... pants extract nutrients and defend against invaders ... fruits and vegetables. Now, scientist have discovered that ... seeds; thus ensuring that sprouting plants are colonized ... of Notre Dame, presented their findings today at ...
Breaking Biology News(10 mins):Asthma symptoms kicking up? Check your exposure to air pollution 2Gut bacteria promote obesity in mice 2Plants prepackage beneficial microbes in their seeds 2
... volume transmitted every second with every quick eye movement ... Ruhr-Universitt Bochum (RUB) and the University of Osnabrck describe ... visual cortex, the entry point for the visual information ... ". Deploying novel optical imaging methods, they demonstrated that ...
... University researchers have shown natural radioactivity within DNA can ... mutation. The research, recently published in Biochimica ... looked at natural radioactivity within human DNA on the ... bodies as well as in every living organism across ...
... explanation for how the most common strain of methicillin-resistant ... prominence. Research published in mBio , the online ... that the strain recently acquired a number of genes ... and thrive on the skin where other strains of ...
Cached Biology News:Neurons subtract images and use the differences 2Neurons subtract images and use the differences 3Radioactivity muddles the alphabet of DNA 2MRSA strain gained dominance with help from skin bacteria 2
Shake 'n' Stack Oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual PLUS Shaker Platform)...
... DNA Polymerase I from ... DNA polymerase. The enzyme also ... activities.1 The 5'?3' exonuclease activity ... nicks and gaps in the ...
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... thymus Description: Topoisomerase I relaxes both ... breakage and rejoining of phosphodiester bonds (1,2) . ... to be differentiated by a single nucleotide pair ... active in the absence of Mn 2+ ...
Biology Products: